{"title":"Bimekizumab for the treatment of plaque psoriasis","authors":"S. Chaplin","doi":"10.1002/psb.2003","DOIUrl":null,"url":null,"abstract":"Bimekizumab (Bimzelx) is an anti‐IL‐17A and ‐17F monoclonal antibody for the treatment of moderate to severe plaque psoriasis. This article summarises its efficacy, adverse effects and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/psb.2003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Bimekizumab (Bimzelx) is an anti‐IL‐17A and ‐17F monoclonal antibody for the treatment of moderate to severe plaque psoriasis. This article summarises its efficacy, adverse effects and place in therapy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
